Faron, etusivu

releases and publications

Faron 2023 Half-Year Financial Results

Regulatory

FDA Orphan Drug Designation for Bexmarilimab

Regulatory

Notice of Half-Year Financial Results

Regulatory

Faron to Participate at Canaccord Conference

Grant of options

Insider Transaction Regulatory

Faron to Hold BEXMAB Study Conference Call

BEXMAB study Update

Regulatory

Holding(s) in Company

Shareholder announcement Regulatory

Announcement of Placing

Regulatory

Exercise of options

Regulatory
PreviousNext
Back to top